Quince therapeutics board of directors unanimously rejects unsolicited proposal from echo lake capital

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its board of directors unanimously rejected the unsolicited proposal it received from echo lake capital to acquire quince for $1.60 per share in cash.
QNCX Ratings Summary
QNCX Quant Ranking